- Home
- DCOY vs BIAF Comparison
DCOY vs BIAF Comparison
Compare DCOY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCOY | BIAF |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | 57 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DCOY | BIAF |
|---|---|---|
| Price | $7.70 | $2.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 67.4K | ★ 14.8M |
| Earning Date | 03-23-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.16 |
| 52 Week High | $9.09 | $13.50 |
Technical Indicators
Market Signals| Indicator | DCOY | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 73.72 | 72.83 |
| Support Level | $0.61 | $1.13 |
| Resistance Level | $8.74 | $3.58 |
| Average True Range (ATR) | 0.43 | 0.37 |
| MACD | 0.31 | 0.20 |
| Stochastic Oscillator | 78.50 | 68.45 |
Price Performance
Historical ComparisonAbout DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.